ID: ALA5177584

Max Phase: Preclinical

Molecular Formula: C19H13F3N4O

Molecular Weight: 370.33

Associated Items:

Representations

Canonical SMILES:  FC(F)(F)c1ccc(Oc2ccc(Nc3ncnc4[nH]ccc34)cc2)cc1

Standard InChI:  InChI=1S/C19H13F3N4O/c20-19(21,22)12-1-5-14(6-2-12)27-15-7-3-13(4-8-15)26-18-16-9-10-23-17(16)24-11-25-18/h1-11H,(H2,23,24,25,26)

Standard InChI Key:  PZUJBGVKSHTSSL-UHFFFAOYSA-N

Associated Targets(Human)

Tau-tubulin kinase 1 179 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Tau-tubulin kinase 2 107 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 370.33Molecular Weight (Monoisotopic): 370.1041AlogP: 5.51#Rotatable Bonds: 4
Polar Surface Area: 62.83Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.54CX Basic pKa: 5.81CX LogP: 4.93CX LogD: 4.92
Aromatic Rings: 4Heavy Atoms: 27QED Weighted: 0.50Np Likeness Score: -1.08

References

1. Nozal V, Martínez-González L, Gomez-Almeria M, Gonzalo-Consuegra C, Santana P, Chaikuad A, Pérez-Cuevas E, Knapp S, Lietha D, Ramírez D, Petralla S, Monti B, Gil C, Martín-Requero A, Palomo V, de Lago E, Martinez A, Martinez A..  (2022)  TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.,  65  (2.0): [PMID:34978799] [10.1021/acs.jmedchem.1c01942]

Source